Kura Oncology, Inc. (KURA)

NASDAQ: KURA · IEX Real-Time Price · USD
13.38
-0.34 (-2.48%)
At close: Feb 3, 2023, 4:00 PM
12.18
-1.20 (-8.97%)
After-hours: Feb 3, 2023, 7:26 PM EST
-2.48%
Market Cap 913.85M
Revenue (ttm) n/a
Net Income (ttm) -135.47M
Shares Out 68.30M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 549,105
Open 13.53
Previous Close 13.72
Day's Range 13.26 - 13.77
52-Week Range 10.41 - 19.93
Beta 0.83
Analysts Buy
Price Target 32.87 (+145.67%)
Earnings Date Feb 23, 2023

About KURA

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 127
Stock Exchange NASDAQ
Ticker Symbol KURA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for KURA stock is "Buy." The 12-month stock price forecast is $32.87, which is an increase of 145.67% from the latest price.

Price Target
$32.87
(145.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor

SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

1 week ago - GlobeNewsWire

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated a...

2 months ago - GlobeNewsWire

Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade

The consensus price target hints at an 110.5% upside potential for Kura Oncology (KURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...

2 months ago - Zacks Investment Research

Kura Oncology to Host Investor Event on December 10, 2022

In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New Orleans In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in ...

2 months ago - GlobeNewsWire

Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?

Here is how Kura Oncology (KURA) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

2 months ago - GlobeNewsWire

Wall Street Analysts Think Kura Oncology (KURA) Could Surge 116%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 115.6% in Kura Oncology (KURA). While the effectiveness of this highly sought-after metric is questionable, the...

2 months ago - Zacks Investment Research

Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?

Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting

Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for oral presentation on December 10, 2022 Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for o...

3 months ago - GlobeNewsWire

Kura Oncology Reports Third Quarter 2022 Financial Results

– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH –

3 months ago - GlobeNewsWire

Kura Oncology to Report Third Quarter 2022 Financial Results

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

3 months ago - GlobeNewsWire

Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC –

3 months ago - GlobeNewsWire

Kura Oncology to Participate in H.C. Wainwright Global Investment Conference

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

5 months ago - GlobeNewsWire

7 Cheap Biotech Stocks to Buy Now

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

6 months ago - InvestorPlace

Kura Oncology Reports Second Quarter 2022 Financial Results

– Recommended Phase 2 dose for ziftomenib identified, pending FDA review –

6 months ago - GlobeNewsWire

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

6 months ago - GlobeNewsWire

Kura Oncology to Report Second Quarter 2022 Financial Results

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

6 months ago - GlobeNewsWire

Read Why Did Credit Suisse Raise Price Target On Kura Oncology

Credit Suisse has raised the price target on Kura Oncology Inc (NASDAQ: KURA) to $29 from $27. The analysts say that evidence of an effective and tolerable agent and a clear recommended phase 2 dose f...

7 months ago - Benzinga

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...

9 months ago - GlobeNewsWire

Kura Oncology Reports First Quarter 2022 Financial Results

– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter –

9 months ago - GlobeNewsWire

Kura Oncology to Report First Quarter 2022 Financial Results

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

10 months ago - GlobeNewsWire

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor –

10 months ago - GlobeNewsWire

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition – – Presentations to highlight significant opportunities targeting farnesyl transferase inhibition –

11 months ago - GlobeNewsWire

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –

1 year ago - GlobeNewsWire

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

1 year ago - GlobeNewsWire